Completing data — refresh the page later to see the latest
137975-06-5Cc1ccccc1C(=O)Nc1ccc(C(=O)N2CCCC(N(C)C)c3ccccc32)cc1WRNXUQJJCIZICJ-UHFFFAOYSA-NMozavaptan is a member of benzamides. It has a role as an aquaretic.
DescriptionMozavaptan is an oral vasopressin V2 antagonist that has been launched in Japan for inappropriate antidiuretic hormone secretion syndrome (IADHS), an affliction manifesting as hyponatremia. It joins another nonpeptidic benzazepine, conivaptan, which corrects sodium and water imbalance by blocking the renal V2 receptor resulting in enhanced diuresis, thereby effectively increasing serum sodium concentration. While conivaptan inhibits both V1 and V2 receptors, mozavaptan is significantly more selective for V2 (IC50 of 14nM vs. 1.2 mM for V1).
UsesMozavaptan is a vasopressin-receptor antagonist. It is used in the treatment of congestive heart failure and hyponatremia.
Usesvasopressin V2 receptor antagonist
DefinitionChEBI: Mozavaptan is a member of benzamides.
137975-06-5DTXSID8057641CHEMBL420762CHEBI:135694